<?xml version="1.0" encoding="UTF-8"?>
<p id="Par75">A total of 26 CMGs covering community-acquired suspected bacterial or viral CNS infections met the inclusion criteria for the review (Fig. 
 <xref rid="Fig1" ref-type="fig">1</xref>). The 26 CMGs were produced in Denmark (
 <italic>n</italic> = 2), France (
 <italic>n</italic> = 2), Germany (
 <italic>n</italic> = 2), Ireland (
 <italic>n</italic> = 1), the Netherlands (
 <italic>n</italic> = 1), Norway (
 <italic>n</italic> = 1), Scotland (
 <italic>n</italic> = 1), Spain (
 <italic>n</italic> = 3), the UK (
 <italic>n</italic> = 6), Europe (
 <italic>n</italic> = 3), the USA (
 <italic>n</italic> = 3) and MSF (
 <italic>n</italic> = 1) (Fig. 
 <xref rid="Fig2" ref-type="fig">2</xref>). Ten focused on viral encephalitis/meningoencephalitis, 14 on bacterial meningitis and two on both (Additional file 
 <xref rid="MOESM2" ref-type="media">2</xref>). 
</p>
